Primary Immunodeficiency Diseases (PIDD)

Immunology·MeSH: Primary Immunodeficiency Diseases

Prevalence

5.0 / 100K

7 drugs in development·2 companies·1 clinical trial

Drug Pipeline by Phase

Approved(5)

Drug	Company
cutaquig	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
cuvitru	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
gammagard liquid	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
hizentra	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
xembify	KORU Medical Systems Inc. Common Stock (DE) (KRMD)

Phase 3(2)

Drug	Company
tak-881	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-881	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

BioSniper tracks 7 drugs in development for Primary Immunodeficiency Diseases (PIDD) across 2 companies.

There are 1 clinical trial targeting Primary Immunodeficiency Diseases (PIDD) tracked by BioSniper.

The estimated prevalence of Primary Immunodeficiency Diseases (PIDD) is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.